Eli Lilly

One-line summary: The GLP-1 franchise leader (NYSE: LLY, ~60% US GLP-1 share via Mounjaro/Zepbound), whose volume-elastic unit economics make it the transmission point for consumer-scale drug categories — and which in June 2026 bought Centessa Pharmaceuticals for $6.3B to acquire an orexin program the market reads as a second run at the same playbook.

Valuation (August 28, 2026)

Last: $1,174.61 at the Friday 2026-08-28 4:00 PM EDT NYSE close. From 2026-08-31-eli-lilly-checkpoints-q3-foundayo-bla-bridge (stockanalysis LLY history). 2026-08-29 is Saturday — no Friday-the-29th session.

Gage's judgment (as of 2026-08-31)

Gage, 31 Aug 2026. ~15% up / ~25% down over 12–18 months. Watch, not buy. Gage's judgment, not grain / not issuer fact. Last-price as-of stays the vault last: $1,174.61 (Friday 2026-08-28 4:00 PM EDT). Obvious GLP-1 franchise is priced; room only if Foundayo and Bridge add new patients without ASP collapse. Q3 confirmed Oct 29, 10:00 AM ET. Do not flatten WST/STVN last-prices or Gage onto this page. Not a buy/sell/size. Not a paper sleeve. No source URL — do not invent one.

What it is

Eli Lilly is a large-cap US pharmaceutical company. Within this wiki it appears in three distinct chains: as the originator of the GLP-1 demand shock that reroutes the protein/dairy complex, as the acquirer in the orexin thesis, and as a European-pricing-policy casualty.

Why it matters to stock-market

• Volume-elastic economics are the transmission mechanism. david-ricks in 2026-04-30-earnings-lly-q1-fy2026: "Pretty much every time we reduce pricing, we see a pretty large expansion [in volume]... the unit economics are really driven by fixed costs that are either sunk in the past or unmovable." This is why a Lilly franchise scales into a consumer-sized category rather than staying a specialty drug — and it is the load-bearing assumption under orexin-franchise-to-lly-glp1-playbook-repeat.
• The orexin acquisition. peter-diamandis in 2026-06-29-podcast-moonshots-why-the-us-government-is-blocking-model-releases: "it made news this week when Eli Lilly purchased for $6.3 billion, a company called Centessa Pharmaceuticals. Their drug targets a neuropeptide called Orexin." alexander-wissner-gross in the same source: "This is Eli Lilly seemingly playing the same playbook over again… the GLP1 RAS took Eli Lilly and have made it a terracorn."
• European pricing is a live revenue risk. tess-cameron in 2026-06-26-podcast-biotech-hangout-episode-187-june-26-2026: "We saw... Lilly announced that they were going to reduce investment in Germany." — Lilly's capital-allocation response to Germany's revenue-linked price-cut policy, which the USTR then opened a Section 301 investigation into.
• Distressed-asset buyer. tess-cameron in 2026-06-26-podcast-biotech-hangout-episode-187-june-26-2026 names Lilly among the stalking-horse bidders in the Sangamo bankruptcy asset sale.
• GLP-1 bariatric-substitution winner + Medicare access catalyst. Lilly holds ~60% of the US obesity market (tirzepatide: Mounjaro/Zepbound); oral pill Foundayo (orforglipron) reached the US market April 2026, with ~two-thirds of new oral-GLP-1 volume new to GLP-1 therapy (market expansion, not just switching). The Medicare GLP-1 Bridge Program (CMS window 2026-07-01 through 2027-12-31; Wegovy/Zepbound KwikPen/Foundayo at $50/mo copay) is a dated catalyst expanding the drug TAM structurally away from bariatric surgery. ~3.8M / ~8% of Part D is KFF 2023 claims, after T2D/OSA/MASH/prior-GLP-1 exclusions — not a CMS headcount. CMS pages retrieved for 2026-08-31-eli-lilly-checkpoints-q3-foundayo-bla-bridge publish no eligible-headcount. From 2026-07-20-autoresearch-health-coverage-glp1-deferred-procedures-tickers (already KFF) and the 2026-08-31 correction. This is the winner leg of glp1-substitution-to-bariatric-surgery-decline.

The "Amazonification" — reinventing pharma (Biotech Hangout Ep 189, 2026-07-17)

The panel reads Lilly as remaking itself from a traditional drug maker into something closer to a tech company — acquiring across every category, shifting toward prevention over treatment, and disintermediating the PBMs.

• $2.8B upfront ($3.8B w/ $1B CVR) acquisition of Atai Beckley, a psychedelics company — lead asset is a nasally-administered treatment for treatment-resistant depression, currently in pivotals (buying ahead of the readout). john-maraganore in 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026: "the news this week for Lilly was around the Thai acquisition... a $3.8 billion acquisition, 2.8 billion upfront and 1 billion linked to a... CBR... it's a category that is proving to be pretty important for people with... treatment resistant depression." First deal under Lilly's new neuroscience-franchise head (Carol, poached from Denali).
• "Amazonification" / going into every category. sam-facelli in 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026: "they seem to be going in every possible area of pharma now... this is the third PNS type disease that's outside of... neurodegeneration. And I think it speaks volumes to how they're thinking about the future which will inevitably include some kind of plateau or pressure on their obesity franchise." — i.e. deliberate diversification against eventual GLP-1 franchise decay (patent cliff ~10 years out).
• Prevention-over-treatment + PBM disintermediation. john-maraganore in 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026: Lilly is going "from something that's a traditional drug maker to something that's frankly closer to a tech company," with a "shift to focusing on prevention of disease as opposed to treatment," and Lilly Direct "integrates telehealth and direct to consumer... effectively going around the PBMs." Cross-links pbm-profit-pool-migration — a manufacturer routing around the PBM channel entirely.

MFN/DTC pricing regime — LLY the relative winner vs NVO (2026-07-27)

From 2026-07-27-autoresearch-us-healthcare-biotech-forcing-functions-july-2026: under the 2026 most-favored-nation / direct-to-consumer regime (17 voluntary MFN deals covering ~86% of the US branded market; TrumpRx DTC portal; GLP-1 Medicare/Medicaid price set at $245/mo; Medicare obesity coverage live 1 July at $50 copay), price falls but volume expands — so the LLY/NVO trajectories diverge. LLY sees revenue accelerating; novo-nordisk guided 2026 sales/profit down 5–13%. Goldman projects LLY's oral orforglipron at ~60% ($13.6B) of the 2030 oral GLP-1 share vs Novo's pill at 21% (duopoly ~85%); orforglipron ATTAIN-1 Phase 3 showed 12.4% (27.3 lb) weight reduction at 72 weeks, planned cash price ~$399/mo. The most durable tradeable second-order effect (peptide-CDMO capacity scarcity) routes into biosecure-cdmo-scarcity-to-western-cdmo-pricing-power / thermo-fisher rather than the drug names, whose pricing outcomes are now largely known.

Q2 FY2026 (call 2026-08-05) — first-party update

From 2026-08-05-earnings-lly-q2-fy2026:

• Revenue +48% YoY; gross margin 86.3% (+~1.3pp); non-GAAP performance margin 54.8% (+9pp); non-GAAP EPS $8.38 (vs $6.31), including acquired IPR&D charges. Key products grew $6.8B.
• MOUNJARO + ZEPBOUND: $14.9B in the quarter. US obesity prescriptions +78% YoY; Lilly ~60% of total and ~70% of injectable scripts. Oncology, immunology and neuroscience together +121% YoY.
• FY2026 guidance raised: lucas-montarce — "We now expect full-year revenue to be between $85 billion and $87 billion" and "non-GAAP earnings per share of $35.50-$36.50, an increase of $2.78 per share at the midpoint."
• Retatrutide — dan-skovronsky: "In TRIUMPH-1, we saw weight loss approaching bariatric surgery levels at the highest doses." US BLA submission planned Q1 2027; dave-ricks notes classification litigation is ongoing. See glp1-substitution-to-bariatric-surgery-decline.
• Foundayo (oral) — prescriber base 8,000 → 36,000 (ilya-yuffa); commercial access across all three major PBMs secured in June, then broad DTC marketing (dave-ricks); ~25% of new starts on the oral, while "around 80% of people that are getting treatment are injectable."
• Medicare GLP-1 Bridge — dave-ricks: "granting 20 million eligible Americans insurance coverage… 35% more people now have coverage." ⚠ Corrected 2026-08-31: the wiki's operative 3.8M is KFF 2023 claims, not CMS. Ricks's 20M / 35% is a Lilly call print of a different denominator. See 2026-08-31-eli-lilly-checkpoints-q3-foundayo-bla-bridge and the contradiction recorded in glp1-injectable-supply-chain-bottleneck.
• Admitted risk (the falsifier): lucas-montarce — "U.S. price declined by 3%, driven by ZEPBOUND and MOUNJARO", and CVS formulary access "will drive basically...price to actually go down...we are going to more than offset that with volume growth."
• Manufacturing: first dedicated genetic-medicine facility opened in Lebanon, Indiana; first commercial batch at Limerick, Ireland. Ex-US supply — patrik-jonsson: "There will be no gating of launches either."
• BD: acquired AtaiBeckley (psychiatry), Curevo, LimmaTech Biologics, and The Vaccine Company.

Checkpoints (2026-08-31) — attach, do not recap Q2

From 2026-08-31-eli-lilly-checkpoints-q3-foundayo-bla-bridge. Q2 block above is left as filed.

• Q3 call confirmed: Lilly IR "Q3 2026 Earnings Call" — October 29, 2026 at 10:00 AM EDT. Dated hint added to EARNINGS.md.
• Foundayo mix is call, not 8-K. Yuffa: ~1-in-4 new starts on Foundayo; ~80% of people getting treatment are injectable. These are different bases — do not write "25% of the franchise is oral." 8-K prints Foundayo $98M, not the mix.
• Bridge window (CMS): 2026-07-01 through 2027-12-31; $50 copay; outside Part D. 3.8M is KFF 2023, not CMS. CMS has not published an eligible-headcount. Klomp "single-digit millions" is quoted by KFF, not independently retrieved as a CMS transcript. Ricks 20M / 35% is Lilly call. Actual Bridge scripts: none-found.
• BLA Q1 2027 still Lilly paper (8-K Ex. 99.1 + 2026-07-23 PR + Skovronsky). S.D. Ind. 1:24-cv-01503 (SO ORDERED 9/30/2025): protein = drug upheld; analogous-to-protein vacated/remanded. 7th Circuit 09-24 not confirmed (not retrieved from PACER / CourtListener / ca7 calendar). Classification delay is the break — do not re-score TRIUMPH.
• Confirm into Q3: volume still offsets guided US price decline; Foundayo mix up without ASP collapse (new patients, not a closed injectable pool); BLA path intact (no refuse-to-file, no public FDA reaffirmation that forces NDA, no CMC slip past Q1 2027).
• Breaks: BLA rejected → NDA slip; oral cannibalizes without new patients; Bridge stays tiny vs 3.8M KFF (open — no fill census).
• Orexin: orexin-franchise-to-lly-glp1-playbook-repeat stays linked, not expanded.
• Hardware last-prices / Gage stay on wst and stevanato. Not a trade. No buy/sell/size.

Update (2026-09-17) — Novartis Lp(a) miss is a rival readout, not a Lilly re-rate.

tess-cameron / Yaron Werber in 2026-09-17-podcast-biotech-hangout-episode-195-september-11-2026 (Ep 195, published 15 September, tape from 11 September): Novartis/Ionis pelacarsen Horizon miss (data dropped Friday 4:30 p.m. into Labor Day); Novartis ~−14%; Amgen "loose 10% on Tuesday" on the read-through. Werber: Amgen and Lilly "both have targeted therapies that drastically reduce lp" and remain "very legitimate players" — the bar for CV outcomes just got harder. Cameron: Structured Therapeutics oral amylin SAD 10 mg 3.33% body-weight loss disappointed vs excitement around Lilly's injectable amylin (eloransertib / "Iloranti" in the transcript). Do not re-rate LLY. Do not mint a new cardiovascular chain. Compounded-GLP-1 warning-letter color is already on this page's policy file.

Update (2026-09-21) — FOIA MFN carveout keeps Mounjaro/Zepbound out of certain discounts. Attach, do not re-rate.

From 2026-09-21-autoresearch-lilly-mfn-foia-glp1-carveout (WaPo / Public Citizen FOIA, recapped Sep 19): Lilly's MFN / TrumpRx contract excludes Mounjaro and Zepbound from the definition of products subject to certain most-favored-nation discounts. A similar Novo carveout is sized at ~$1.7B of potential Medicaid savings. Deals run through January 20, 2029. A Lilly spokesperson pointed to expanded access for Zepbound and Foundayo — company frame, not a volume print. Consistent with "pricing risk is admitted, franchise is protected," not a new forcing function. Do not graduate a new LLY chain. Do not re-rate LLY.

Houston Foundayo API groundbreak (2026-09-21) — attach-only

From 2026-09-23-china-oil-import-cut-destocking-lilly-houston (Lilly PR, Sep 21 2026): broke ground on the previously announced $6.5 billion Houston / Generation Park API site for Foundayo (orforglipron) and other small-molecule medicines. Original plan: Lilly IR, Sep 23 2025. Dated construction start, not a 2026 volume print. Do not re-rate LLY.

Related

• orexin-franchise-to-lly-glp1-playbook-repeat — the hypothesis chain built on the Centessa deal.
• novo-nordisk — the GLP-1 pricing-regime relative loser (pair trade)
• biosecure-cdmo-scarcity-to-western-cdmo-pricing-power — where the GLP-1 volume second-order effect (peptide CDMO scarcity) routes
• glp1-injectable-supply-chain-bottleneck — the picks-and-shovels chain downstream of Lilly's franchise.
• glp1-protein-demand-to-cheese-glut — the consumer second-order chain.
• german-drug-pricing-to-section-301-retaliation — the policy risk chain.
• glp1-substitution-to-bariatric-surgery-decline — the bariatric-substitution chain where LLY is the winner.
• john-maraganore · sam-facelli — panelists on the Amazonification read.
• 2026-08-31-eli-lilly-checkpoints-q3-foundayo-bla-bridge — Q3 date, last-price, Bridge KFF correction, BLA/court attach.